USP: Draft for a Cannabis Monograph
The United States Pharmacopeia (USP) has opened a 90-day review period for their proposed Cannabis Species Inflorescence Monograph in the Herbal Medicines Compendium (HMC), a laboratory quality standards testing reference used internationally.
The proposed cannabis monograph provides scientifically validated methods, information on physical reference standards, and acceptance criteria to establish the identity of cannabis chemotypes, content of cannabinoids and terpenes, and limits on contaminants.
“Cannabis is becoming more widely accepted around the world and is being widely researched by many international organizations for medicinal purposes. A key component of USP’s mission to improve global health is providing public standards and guidance to help ensure the quality of all medicines, including herbal medicines,” said Dr. Jaap Venema, USP’s Chief Science Officer.
The comment end date for the draft monograph is December 20, 2022.
Sources:
mg magazine: Press Release
USP: Cannabis Species Inflorescence, Proposed For Comment Version 0.1
Meet the GMP Compliance Adviser
The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business.
The demo access is non-binding and ends automatically.
You may also be interested in the following articles:
